NCT03184558 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

August 20, 2018

Study Completion Date

August 20, 2018

Conditions

Triple Negative Breast CancerInflammatory Breast Cancer Stage IV

Interventions

DRUG

Bemcentinib; pembrolizumab

Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.

Trial Locations (17)

5021

Haukeland University Hospital, Bergen

25198

Hospital Universitario Amau de Vilanova de Lieda, Servicio de Oncologia, Lleida

28007

Hospital General Universitario Gregorio Maranon, Madrid

28034

Hospital Universitario Ramon y Cajal, Madrid

50009

Hospital Universitario Miguel Servet, Zaragoza

64111

Saint Luke's Cancer Institute, Kansas City

91010-3012

City of Hope Cancer Center, Duarte

92123-2701

Sharp memorial Hospital, 7901 Frost Street,, San Diego

03756

Dartmouth-Hitchcock Medical Center, Lebanon

15232-1309

Magee-Womens Hospital, UPMC Cancer Pavilion, Pittsburgh

03010

University General Hospital of Alicante, Alicante

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

08916

Hospital Universitario Germans Trias i Pujol - Institut Catala d'Oncologia, Barcelona

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

W6 8RF

Imperial College Healthcare NHS Trust, Charing Cross Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

NG5 1 PB

Nottingham University Hospitals, City Campus, Hucknall Road, Nottingham